Skip to main content

Nivolumab (Opdivo & Opdyta) Injection Online | Blueberry pharmaceuticals

NIVOLUMAB

Nivolumab belongs to a group of cancer drugs known as monoclonal antibodies. Nivolumab is also known as an immune checkpoint inhibitor. Sometimes these drugs are called targeted therapies because they target specific proteins (receptors) on the surface of cells. Nivolumab is a prescription drug which is used under the supervision of a doctor

INDICATION

Nivolumab is indicated for the treatment of patients having Melanoma. Nivolumab is indicated for the treatment of patients having Non-Small Cell Lung Cancer. Nivolumab is indicated for the treatment of patients having Kidney (Renal Cell) Cancer.

MECHANISM OF ACTION

Nivolumab prohibits the molecule activity called PD-1, and it is a protein which prevents T cells from recognizing and attacking inflamed tissues and cancer cells. PD-1 can deceit the immune system into overlooking melanoma cells as normal cells.

DOSAGE AND ADMINISTRATION

Nivolumab recommended dosage for unresectable or metastatic melanoma :
As a single agent is either 240mg every 2 weeks or 480mg every 4 weeks given as IV infusion over 30 minutes until disease progression or unacceptable toxicity
With ipilimumab. The recommended dose of Nivolumab is 1mg/kg administrated as an intravenous infusion over 30 minutes, followed by ipilimumab 3mg/kg given as IV over 90 minutes on the same day. Duration 3 weeks of max 4 doses, after completing combination does continue the single agent treatment.

COMMON SIDE EFFECTS

Fatigue
Lymphocytopenia (Low White Blood Cells)
Low Sodium
Shortness of breath
Musculoskeletal Pain
Decreased Appetite
Cough

PRECAUTIONS

Immune-mediated pneumonitis may appear to the patients; withhold for moderate and permanently discontinue for serious or life-threatening pneumonitis Other clinically significant and possible fatal immune-mediated side effects (eg, myocarditis, rhabdomyolysis, myositis, uveitis, iritis, pancreatitis) can appear after therapy discontinuation. Serious infusion reactions resulted (rare, <1%); stop if severe or life-threatening; break or slow rate of infusion in patients with mild or moderate infusion reactions

STORAGE

Store at under refrigeration at 2°C to 8°C.

MISSED DOSE

If you missed a dose take it as soon as possible, if time reach for next dose, then skip the missed dose and continue regular schedule. Avoid taking two doses at a time. Avoid taking a missed dose within 12hrs of the next dose.

FOR MORE INFORMATION:

EMAIL:
info@blueberrypharma.com

PHONE:
+91-97890 77748

VISIT US:
Labels:

Comments

Post a Comment

Popular posts from this blog

EVEROLIMUS TABLETS COST IN INDIA

EVEROLIMUS DESCRIPTION  Everolimus  belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor).  Everolimus  is an immunosuppressive macrolide. EVEROLIMUS USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with  Everolimus .  Everolimus  is used in the advanced stage of breast cancer. Neuroendocrine tumors  Everolimus involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer Patient treating with  Everolimus  after the failure of treatment with Sunitinib or Sorafenib.  Everolimus  also used in the condition of Heart, liver, kidney transplantation, Waldenstrom macroglobulinemia, Other carcinoid tumors Brand: Evertor Strength: 10mg Ingredient: Everolimus Company Name: Biocon Tab Count: 10 Tablets MECHANISM OF ACTION Everolimus  is the prohibition o
1 comment
Read more

Everotas 5 mg | Everolimus | Blueberry pharmaceuticals

DESCRIPTION Everotas 5mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Everotas 5mg is an immunosuppressive macrolide. USED FOR Breast cancer  The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Everotas. Everotas 5mg is used in an advanced stage of breast cancer. Neuroendocrine tumors  Everotas 5mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer. Renal cell cancer  Patient treating with Everotas 5mg after the failure of treatment with Sunitinib or Sorafenib. Everotas 5mg also used in the condition of; Heart, liver, kidney transplantation Waldenström macroglobulinemia Other carcinoid tumors. MECHANISM OF ACTION Everotas is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase. Everotas bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with
Post a Comment
Read more